Dihydropyrimidine Dehydrogenase Deficiency: To Screen or Not to Screen?

5-fluorouracil (5-FU) and its prodrug capecitabine are frequently prescribed in oncology. While usually well tolerated, toxicity can be severe, and even life-threatening. A dihydropyrimidine dehydrogenase (DPD) deficiency can cause severe toxicity. Current testing for DPD deficiency does not meet th...

Descripción completa

Detalles Bibliográficos
Autores principales: Vogel, Wendy H., Minhas, Ahmed, Baumrucker, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2020
Materias:
Grand Rounds
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7517765/
https://www.ncbi.nlm.nih.gov/pubmed/33542850
http://dx.doi.org/10.6004/jadpro.2020.11.1.4
Descripción
Sumario:5-fluorouracil (5-FU) and its prodrug capecitabine are frequently prescribed in oncology. While usually well tolerated, toxicity can be severe, and even life-threatening. A dihydropyrimidine dehydrogenase (DPD) deficiency can cause severe toxicity. Current testing for DPD deficiency does not meet the criteria for a routine screening test prior to 5-FU therapy. A case study of a fatality secondary to capecitabine toxicity is reviewed and literature is examined regarding general screening for DPD deficiency.

Ejemplares similares